Novartis stock closed flat Friday after the drugmaker beat fourth-quarter expectations, largely on the back of its heart failure drug Entresto.

Drugmakers have raised the list prices of more than 800 prescription drugs — ranging from blood pressure medications to cancer treatments — by a median of 4% at the start of this year, The Wall Street ...